Firm
Executive chair Matt Dixon, who reveals a new associate hire, says the firm wants to offer a realistic pathway to partnership while avoiding the ‘corporate machine’ route
Mayer Brown’s role in cardiovascular technology dispute reflects how firms are pursuing precedent-setting cases to try and guide AI and patent law
Practitioners believe new AI tools at the USPTO will not replace lawyers or disrupt revenue, but instead expose where a trademark attorney’s value lies
UKIPO rejects trademark application for 'Cristiano Ronaldo Origins' following opposition by Beck Greener client in a rare case that considered actual use
Sponsored
Sponsored
-
Sponsored by InventaInês Monteiro Alves of Inventa analyses the trademark implications resulting from the acquisition of the fact-checking TV programme from the broadcaster SIC -
Sponsored by United Trademark & Patent ServicesM Talal Farrukh Irfan Khan of United Trademark & Patent Services explores the UAE’s evolving approach to AI regulation, combining federal and sector-specific legislation, free zone frameworks, and national policy initiatives
-
Sponsored by Hanol IP & LawA landmark case involving the remodelling of luxury brand bags at the owner’s request has established legal principles on the trademark implications of such services, explains Min Son of Hanol IP & Law
-
Sponsored by Patrinos & KilimirisMaria Kilimiris of Patrinos & Kilimiris explains a recent decision regarding how genuine use is assessed for trademarks registered across broad categories of goods and their subcategories
-
Sponsored by Berken IPMaría Aurora García of Berken IP examines how Argentine courts are using dynamic injunctions to tackle illegal sports streaming, particularly in the context of major events such as the football World Cup
-
Sponsored by Bird & BirdAnnika Lückemann and Jan van Dieck of Bird & Bird analyse the Unified Patent Court’s opening ruling concerning a supplementary protection certificate, highlighting procedural peculiarities, urgency considerations, and possible implications for pharmaceutical originator-generic disputes
